WE CLAIM:

1. A pharmaceutical formulation in the form of an infusion concentrate comprising discodermolide and a pharmaceutically acceptable organic solvent selected from an alcohol.

2. A pharmaceutical formulation according to Claim 1, wherein the pharmaceutically acceptable organic solvent is a propylene glycol.

3. A pharmaceutical formulation according to Claim 1, wherein the discodermolide is at a concentration of 0.1-20 mg/mL.

4. A pharmaceutical formulation according to Claim 1, wherein the discodermolide is at a concentration of 0.6-3 mg/mL.

5. A pharmaceutical formulation according to Claim 1, wherein the discodermolide is at a concentration of 2 mg/mL.

6. An infusion solution comprising an infusion concentrate according to Claim 1 and a diluent vehicle selected from a mixture of saline and pharmaceutically acceptable solvents and mixtures thereof.

7. An infusion solution according to Claim 6, wherein the solvent is selected from propylene glycol, ethanol, benzoic acid, benzoate, benzyl alcohol and mixtures thereof.

8. An infusion solution according to Claim 6, wherein the diluent vehicle is selected from ethanol in saline.

9. An infusion solution according to Claim 6, wherein the diluent vehicle is 10-20% $^{w}/_{v}$ ethanol in saline.

10. An infusion solution according to Claim 6, wherein the diluent vehicle is 16.3% $^{w}/_{v}$ ethanol in saline.

11. A pharmaceutical kit comprising an infusion concentrate of discodermolide in an organic solvent and a diluent vehicle.

12. A pharmaceutical kit comprising an infusion concentrate of discodermolide in an organic solvent and a diluent vehicle wherein the infusion concentrate and diluent vehicle are in separate containers.

13. A method of administering discodermolide to a subject in need of discodermolide treatment which comprises administering parenterally an infusion solution according to Claim 6 to a subject in need of such treatment.

14. A method of administering a discodermolide for the treatment of a proliferative disease, sensitive to treatment with discodermolide, to a mammal in need of such treatment in a therapeutically effective amount which comprises:

(a) diluting an infusion concentrate according to Claim 1 with a diluent vehicle to form an infusion solution; and

(b) administering the infusion solution by i.v. to the subject.

15. A method of administering a discodermolide for the treatment of a proliferative disease sensitive to treatment with discodermolide to a mammal in need of such treatment in a therapeutically effective amount which comprises:

(a) diluting an infusion concentrate comprising discodermolide with a diluent comprising 16.3% $^{w}/_{v}$ ethanol in saline to form an infusion solution; and

(b) administering the infusion solution by i.v. to the subject.

16. A method of administering a discodermolide for the treatment of a proliferative disease sensitive to treatment with discodermolide to a mammal in need of such treatment in a therapeutically effective amount which comprises:

(a) diluting a 2 mg/mL infusion concentrate comprising discodermolide with a diluent comprising 16.3% $^{w}/_{v}$ ethanol in saline in a 1:1.6 ratio to form an infusion solution; and

(b) administering the infusion solution by i.v. to the subject.

17. A method according to Claim 14, wherein step (a) is completed 8 hours or less prior to administration.

18. A method of preparing a infusion solution for administration comprising:

(a) preparing a solution of discodermolide in an organic solvent; and

(b) diluting the solution of step (a) with a vehicle comprising saline and ethanol, wherein step (b) is done 8 hours or less prior to administration.